Canakinumab Drug Phase III Study Reducing Heart Attacks

Canakinumab Drug Phase III Study Reducing Heart Attacks

Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack

  • Phase III CANTOS study met the primary endpoint, a composite of heart attack, stroke and cardiovascular death, showing that ACZ885 (canakinumab) in combination with standard of care therapy reduces cardiovascular risk in people with a prior heart attack and inflammatory atherosclerosis
  • Despite current treatments about 40% of heart attack survivors remain at increased risk of  recurrent heart attack, stroke or cardiovascular death because of high-risk inflammatory atherosclerosis[1]; 25% experience another event within five years[2]

 

Basel, June 22, 2017 – Novartis today announced topline results from the global Phase III CANTOS study investigating the efficacy, safety and tolerability of ACZ885 (canakinumab) in combination with standard of care in people with a prior heart attack and inflammatory atherosclerosis. With more than 10,000 patients enrolled in the study over the last six years, CANTOS is one of the largest and longest-running clinical trials in Novartis’ history.

The CANTOS study met the primary endpoint, demonstrating that when used in combination with standard of care ACZ885 reduces the risk of major adverse cardiovascular events (MACE), a composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke, in patients with a prior heart attack and inflammatory atherosclerosis. The full data from the study will be submitted for presentation at a medical congress and for peer reviewed publication later this year.

“Despite current treatment, about 25 percent of heart attack survivors will have another cardiovascular event within five years, making the outcome of the CANTOS study a promising new development for patients,” said Vas Narasimhan, Global Head, Drug Development and Chief Medical Officer, Novartis. “ACZ885 is the first and only investigational agent which has shown that selectively targeting inflammation reduces cardiovascular risk. Our priority now is to thoroughly analyze these important data and discuss them with regulatory agencies.”

Heart attack occurs in about 580,000 people every year in EU5 and 750,000 people in the United States alone[3],[4]. In 2015 there were an estimated 7.29 million heart attacks globally[5]. Despite standard treatment, people with a prior heart attack live with a higher ongoing risk of having another event or dying, and it has been shown that in about four in 10 people, this risk is directly related to increased inflammation associated with atherosclerosis[1]. The recurrent MACE in patients with inflammatory atherosclerosis are associated with increased morbidity, mortality and reduced quality of life and currently represent a major economic burden on patients and healthcare systems around the world.

About CANTOS
The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) (NCT01327846) is a randomized, double-blind, placebo-controlled, event-driven Phase III study designed to evaluate the efficacy, safety and tolerability of quarterly subcutaneous injections of ACZ885 (also known as canakinumab) in combination with standard of care in the prevention of recurrent cardiovascular (CV) events among 10,061 people with a prior myocardial infarction (MI) and with a high-sensitivity C-reactive protein (hsCRP) level of >=2mg/L. The study evaluated three different doses of ACZ885 vs placebo. The primary endpoint of the study was time to first occurrence of major adverse CV event (MACE), a composite of CV death, non-fatal MI, and non-fatal stroke. Secondary endpoints included time to first occurrence of the composite CV endpoint consisting of CV death, non-fatal MI, non-fatal stroke and hospitalization for unstable angina requiring unplanned revascularization; time to new onset type 2 diabetes among people with pre-diabetes at randomization; time to occurrence of non-fatal MI, non-fatal stroke or all-cause mortality; and time to all-cause mortality. The median follow-up time was 3.8 years. The study ran for approximately six years.

About heart attack and inflammatory atherosclerosis
Heart attack occurs in about 580,000 people every year in EU5 and 750,000 people in the United States alone[3],[4]. In 2015 there were an estimated 7.29 million heart attacks globally[5]. Despite standard treatment, patients who have had a prior heart attack live with a higher ongoing risk of secondary major adverse cardiovascular events (MACE), a composite of cardiovascular (CV) death, non-fatal MI, and non-fatal stroke. It has been shown that in about four in 10 people, this risk is directly related to the increased inflammation associated with inflammatory atherosclerosis as measured by a high-sensitivity C-reactive protein (hsCRP) biomarker level of >= 2mg/L[1]. The recurrent MACE in people with inflammatory atherosclerosis are associated with increased morbidity, mortality and reduced quality of life and currently represent a major economic burden on patients and healthcare systems around the world.

About ACZ885
ACZ885 (canakinumab) is a selective, high-affinity, fully human monoclonal antibody that inhibits IL-1ß, a key cytokine in the inflammatory pathway known to drive the continued progression of inflammatory atherosclerosis[6]-[10]. ACZ885 works by blocking the action of IL-1ß for a sustained period of time, therefore inhibiting inflammation that is caused by its over-production[11],[12]. ACZ885 is the first and only agent which has shown that selectively targeting inflammation significantly reduces cardiovascular risk in patients who have had a prior heart attack and have an increased cardiovascular inflammatory burden.

 


 

References
[1] Ridker P. How Common Is Residual Inflammatory Risk? Circ Res. 2017;120:617-619
[2] Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017;135:e146-e603
[3] EU5 MI trend. Based on Eurostat discharge data. Novartis data on file.
[4] Mozaffarian D, et al. Heart Disease and Stroke Statistics – 2016 Update: A Report From the American Heart Association. Circulation. 2017; 135(23):e1-324.
[5] Roth G, et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. JACC. Available online May 17, 2017.
[6] Fearon WF, Fearon DT. Inflammation and cardiovascular disease: role of the interleukin-1 receptor antagonist. Circulation. 2008;117:2577-2579.
[7] Duewell P, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464(7293):1357-61.
[8] Rajamaki K, et al. Cholesterol Crystals Activate the NLRP3 Inflammasome in Human Macrophages: A Novel Link between Cholesterol Metabolism and Inflammation. PLoS One. 2010; 5(7):e11765.
[9] Ridker PM, Luscher TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J. 2014; 35(27):1782-91.
[10] Ridker PM. From C-Reactive Protein to Interleukin-6 to Interleukin-1. Circ Res. 2016; 118:145-156.
[11] Ridker PM, et al. Effects of Interleukin-1ß Inhibition with Canakinumab on Hemoglobin A1c, C-Reactive Protein, Interleukin-6 and Fibrinogen. Circulation. 2012; 126(23):2739-48.
[12] Ridker PM, et al. Interleukin-1ß inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011; 162(4):597-605.


Spurce: http://bit.ly/2sZOlrt

Beetroot Juice May Provide Benefits to Heart Disease Patients

Beetroot Juice May Provide Benefits to Heart Disease Patients

Nitrate supplementation [Beetroot Juice] decreases sympathetic nerve responses that contribute to heart disease risk

Bethesda, Md. (May 10, 2017)—A new study finds that dietary nitrate—a compound that dilates blood vessels to decrease blood pressure—may reduce overstimulation of the sympathetic nervous system that occurs with heart disease. The research team looked specifically at beetroot juice, a source of dietary nitrate, to explore its use as a future targeted treatment option for people with cardiovascular disease. The study, published ahead of print in the American Journal of Physiology—Heart and Circulatory Physiology, is the first to study the effects of nitrate supplementation on sympathetic nerve activity.

Activation of the sympathetic nervous system—caused by increased sympathetic nerve activity—results in elevated heart rate and blood pressure and blood vessel constriction. Sympathetic nerve activity (sympathetic outflow) also increases with some forms of cardiovascular disease, including high blood pressure and heart failure. The aim of the study was to show that “acute nitrate supplementation using beetroot juice can decrease muscle sympathetic outflow at rest and during exercise,” the Canadian research team wrote.

Twenty young adult volunteers (average age: 27) participated in two separate testing visits in which they blindly received either a nitrate supplement or a placebo. On both visits, the research team recorded the blood pressure, heart rate and muscle sympathetic nerve activity (MSNA) and measured muscle activity at rest and during handgrip exercise with the participants’ non-dominant hand. Measurements were recorded at the beginning of the visit and then again after the volunteers drank nitrate-rich beetroot juice or a placebo and had rested on their backs for three hours.

MSNA burst rate, denoting the frequency of nerve activity, was lower when the volunteers drank beetroot juice compared to when they drank the placebo. Sympathetic nerve activity also decreased during exercise. “Surprisingly, no differences in blood pressure were detected at rest or during exercise,” the research team noted. “These results provide proof-of-concept that dietary nitrate supplementation can modulate central sympathetic outflow and suggest that the established cardiovascular benefits [of dietary nitrate] are likely to involve a neural contribution.”

The article, “Acute beetroot juice supplementation on sympathetic nerve activity: A randomized, double-blind, placebo-controlled proof-of-concept study,” is published ahead of print in the American Journal of Physiology—Heart and Circulatory Physiology.


 

Pumping Marvellous Note: Remember that Beetroot is incredibly easy to grow at home in the UK, and needs little maintenance beyond the initial sow and thinning. Choose a hardy variety like Boltardy or one of the may other delicious varieties. Give it a grow!

Click here for more heart news >

Favourable Effects of Vitamin D in Chronic Heart Failure - VINDICATE Study Dr Klaus Witte

Favourable Effects of Vitamin D in Chronic Heart Failure – VINDICATE

Favourable effects of vitamin D on cardiac function in patients with chronic heart failure secondary to left ventricular systolic dysfunction – the results of the MRC-funded VINDICATE Study

A daily dose of vitamin D3 improves heart function in people with chronic heart failure, a five-year University of Leeds research project has found. Dr Klaus Witte, from the Leeds University School of Medicine and Leeds Teaching Hospitals NHS Trust, led the study, known as VINDICATE, and here share his thoughts with us and our heart failure community.

“This is a significant breakthrough for patients. It is the first evidence that vitamin D3 can improve heart function of people with heart muscle weakness – known as heart failure. These findings could make a significant difference to the care of heart failure patients,” said Dr Witte.

 

Chronic heart failure is due to reduced pumping function of the heart and affects about 900,000 people in the UK and more than 23 million worldwide. The condition can affect people of all ages, but it is more common in older people – more than half of all people globally with heart failure are over the age of 75.

 

The most frequent cause of heart failure is heart muscle damage following a heart attack although high blood pressure, heart valve problems and infections can also lead to heart failure. The weakness is reflected by symptoms of shortness of breath and fatigue. Despite very good therapies including tablets and in some patients special pacemakers, many people with heart failure have persistent symptoms, and the heart muscle weakness remains.

 

“We found that almost all patients with heart failure in Leeds were deficient in vitamin D and that the degree of deficiency related to markers of severity. Vitamin D3 levels are largely dependent upon exposure to sunlight, yet levels are low throughout the year because heart failure patients are often older, spend less time in the sun, and also make less vitamin D3 in response to sunlight than younger people. Vitamin D3 production in the skin is also reduced by sunscreen.”

 

Vitamin D is known to have bone strengthening effects by improving calcium deposition in the skeleton, yet the substance is involved in many other systems, including muscle contraction, immune function, and insulin release, all of which may be abnormal in patients with heart failure. Up until now, there were no data suggesting that replacing vitamin D has any benefit in patients with heart problems.

 

The study, which was funded by the Medical Research Council, involved more than 160 patients from Leeds who were already being treated for their heart failure using proven treatments including beta-blockers, ACE-inhibitors and pacemakers.

Participants were asked to take 4,000 IU [100 μg] vitamin D3 or a dummy (placebo) tablet daily for one year. Those patients who took vitamin D3 experienced an improvement in heart function which was not seen in those who took a placebo.

 

Dr Klaus Witte and team, from the Leeds University School of Medicine and Leeds Teaching Hospitals NHS Trust

 

Changes in heart function were measured by cardiac ultrasound (known as an echocardiogram). This allows us to measure how much blood pumps from the heart with each heartbeat, known as ejection fraction. The ejection fraction of a healthy person is usually between 60% and 70%. In heart failure patients, the ejection fraction is often significantly lower – in the patients enrolled into the VINDICATE study the average ejection fraction was 26%. In the 80 patients who took Vitamin D3, the heart’s pumping function improved from 26% to 34%. In the others, who took placebo, there was no change in cardiac function.

 

“One key aspect of this study is that we avoided using a calcium-based supplement, as calcium can cause further problems for heart failure patients. Crucially, the tablets were well tolerated by our patients and we saw no important side effects on kidney function.”

 

The findings from the VINDICATE study were presented at the American College of Cardiology 65th Annual Scientific Session & Expo in Chicago on April 4, 2016.

 

“In conclusion, we have shown for the first time that a high dose of vitamin D taken daily is safe and improves heart function in patients with heart failure. The next step is to use the information from this study to find out if improving the heart function reduces hospital admissions and extends the life of patients with heart failure. To this aim we have submitted an application to the National Institute of Health Research in the UK for VINDICATE 2 which will involve 1278 people with heart failure across the country for 4 years. The team at Pumping Marvellous have provided valuable advice in the development of VINDICATE 2 so please check back here to hear about the status of our application and, if funded, the status of the trial,” said Dr Klaus Witte.

 

 

Dr Klaus Witte MD, FRCP, FESC, FACC Associate Professor and Consultant Cardiologist
Dr Klaus Witte MD, FRCP, FESC, FACC

Dr Klaus Witte MD, FRCP, FESC, FACC Associate Professor and Consultant Cardiologist

NIHR Clinician Scientist

University of Leeds and Leeds Teaching Hospitals NHS Trust

 

 

 

 

One year of 4000 IU 25(OH)-Vitamin D3daily in heart failure with impaired cardiac function
One year of 4000 IU 25(OH)-Vitamin D3daily in heart failure with impaired cardiac function
TYRX™ Absorbable Antibacterial Envelope

Infections Down With Antibacterial Envelope for ICD/CRT

Clinical use of antibacterial envelope mesh cuts infection rate for ICD/CRT implants

The TYRX Absorbable Antibacterial Envelope and the TYRXNeuro Absorbable Antibacterial Envelope are the first commercially available implantable medical devices designed to stabilize Cardiac Implantable Devices  [CRTs and ICDs] and Implantable Neurostimulators [INSs] and to help reduce their infection.

Medtronic PLC has signed up more than 140 U.S. hospitals and clinics in a program that aims to cut infection rates in heart devices using its innovative dissolvable surgical antibacterial envelopes and rebates. Medtronic are confident in the Tyrx envelope’s ability to reduce infection rates and are signing “risk sharing” agreements with health care providers [in the US] that say the company will pay a substantial rebate toward the high cost of removing an infected Medtronic device and implanting a new one, if a Tyrx envelope was used in the original surgery and an infection sets in anyway.

Infection rates for pacemakers, implantable defibrillators and cardiac resynchronization therapy (CRT) devices vary. But in general, it is purported that more complex devices like CRTs are more prone to infections, and so are replacement devices, which are placed in the fibrous “capsule” of scarlike tissue that formed around the original device, where it is more difficult to fight infection.

A contemporary absorbable version is currently under evaluation in the prospective World-Wide Randomized Antibiotic Envelope Infection Prevention Trial (WRAP-IT) randomized trial [enrolling now by invitation], with a projected enrollment of more than 7700 patients receiving ICD or CRT upgrades or replacements.

Source: Antibacterial Envelope Is Associated With Low Infection Rates After Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Therapy Device Replacement
Charles A. Henrikson, M. Rizwan Sohail, Helbert Acosta, Eric E. Johnson, Lawrence Rosenthal, Roman Pachulski, Dan Dan, Walter Paladino, Farhat S. Khairallah, Kent Gleed, Ibrahim Hanna, Alan Cheng, Daniel R. Lexcen, Grant R. Simons
JACC: Clinical Electrophysiology May 2017, 388; DOI: 10.1016/j.jacep.2017.02.016 bit.ly/2rivA2r
Iron deficiency in heart failure patients contributes to poor outcomes

Iron Deficiency in Heart Failure Patients Contributes to Poor Outcomes

Patients admitted with acute heart failure who exhibit iron deficiency (ID) tend to have a longer and more expensive hospital stay and a greater likelihood of readmission, according to analysis of Hospital Episode Statistics (HES) in England presented at the British Cardiovascular Society (BCS) conference in Manchester.

The research, which looked at data over three consecutive years, showed that 14 per cent of patients with heart failure also had ID as a secondary diagnosis, and that hospital spells for these patients were significantly more costly than those without ID.

What is heart failure?

Heart failure generally occurs when the heart muscle is damaged, and the heart is unable to pump blood effectively around the body. Those affected often have other conditions as well, such as renal failure and diabetes.

50 per cent of patients

Previous research has shown that ID be present in about 50 per cent of patients and recently updated heart failure treatment guidelines have emphasised the need to screen for this condition and provide effective treatment. However testing for ID remains inconsistent.

Iron plays a vital role in the formation of red blood cells that carry oxygen around the body and in regulating many important processes within cells. ID in those with heart failure appears to worsen symptoms, reduces quality of life and increases mortality risk.

Half a million people

Professor Metin Avkiran, Associate Medical Director at the British Heart Foundation, said:

“Heart failure is a devastating condition which affects approximately half a million people across the UK. These initial findings add to the growing evidence that iron deficiency is a significantly common condition in patients with heart failure and adds to the risks associated with this condition.

“Ongoing BHF-funded studies have shown that iron administered into a vein can be beneficial to patients with heart failure and iron deficiency in the short term, making them feel better and increasing exercise capacity. However, more research is required to understand the link – particularly to establish the role of iron replacement in the treatment of heart failure.”

Press Release :: Heart Failure Nurse's 200km Charity Challenge for Heart Failure Patients

Press Release :: Heart Failure Nurse’s 100km Charity Challenge for Heart Failure Patients

Newham University Hospital Heart Failure Nurse to walk 100K to raise funds for The Pumping Marvellous Foundation, the UK’s Heart Failure Charity

Heart Failure Nurse to Walk the London 2 Brighton 100K Challenge for Heart Failure Patients

Preston, Lancashire, May 2017 – Over May Bank Holiday Weekend 2017, Heart Failure Nurse at Newham University Hospital, Sarah Walsh, will take part in a classic capital to coast challenge.  The event is part of Action Challenge’s Ultra Challenge Series and is billed as “the UK’s greatest endurance challenge”.  Sarah is aiming to walk the entire 100K distance from London to Brighton in 24 hours.

Sarah’s trek will start in Richmond, West London, on the morning of Saturday 27th May.  Her journey will take her along 100 kilometres of paths, trails, the North Downs, the South Downs and some wonderful Sussex countryside before the coastline will come into view.  Sarah will finish her adventure at the finish line down the home straight of Brighton Racecourse on Sunday 28th May.

Sarah has chosen The Pumping Marvellous Foundation as the beneficiary of her fundraising efforts in recognition of all the support that they offer to patients, families and healthcare professionals. “As a Heart Failure Nurse, I frequently give out Pumping Marvellous publications to my patients – these are always very well received. It is great to know that there is somewhere I can direct patients and their families to that will offer extra information and support. I want to do my bit to give back to a charity that is, in my opinion, invaluable.”

If you would like to support Sarah and The Pumping Marvellous Foundation, you can donate via her Just Giving page https://www.justgiving.com/fundraising/100km4heartfailure

Nick Hartshorne-Evans, Founder and CEO of The Pumping Marvellous Foundation, the UK’s Heart Failure Charity said “We are delighted that Sarah, a Heart Failure Nurse, has chosen to support our charity and heart failure patients.  Heart Failure Nurses are so important to heart failure patients and carers and it is marvellous that Sarah is leading from the front.  We wish her the very best of luck in her endeavours.”

Ends – For more information please contact The Pumping Marvellous Foundation +44 (0) 1772 796542 or +44 (0) 7854 407050, hearts@pumpingmarvellous.org

About The Pumping Marvellous Foundation

The Pumping Marvellous Foundation is the UK’s patient driven Heart Failure Charity. It was founded by Nick Hartshorne-Evans, who at 39 was diagnosed with Heart Failure after a viral attack on his heart. He was dismayed that there was not a Heart Failure Charity focussed on the needs of the patient. He set the group up to advocate and provide help and support for people having to manage their Heart Failure, along with their carers and families. The Heart Failure Charity, The Pumping Marvellous Foundation, is led and driven by its Patient Board and guided by the world class Heart Failure Specialists on its Clinical Board.

 

About Heart Failure

Heart failure affects about 410,000 people in England, of whom nearly three quarters (295,800) have heart failure with a reduced ejection fraction.  Common symptoms of heart failure include breathlessness, tiredness and fluid retention. The most common cause of heart failure in the UK is heart disease, with many patients having had a heart attack in the past.

Heart failure causes significant ill-health and death. In 2012/13 over 30,000 people were admitted to hospital in England with heart failure with reduced left ventricular ejection fraction. Around 30-40% of patients diagnosed with heart failure die within a year, but after that the mortality rate falls to less than 10% per year.

New Nano-Polymer Could Prevent Heart Failure

New Nano-Polymer Could Prevent Heart Failure

New Biomedical Polymer Reduces Arterial Plaque and Inflammation

Researchers at Ben-Gurion University and the Sheba Medical Center have developed a new therapy to treat atherosclerosis and prevent heart failure with a new biomedical polymer that reduces arterial plaque and inflammation in the cardiovascular system.

Atherosclerotic cardiovascular disease causes 56 million deaths annually worldwide, according to the 2015 Lancet Global Burden of Disease Report. Arteries are lined by a thin layer of cells called the “endothelium” which keep them toned and smooth and maintain blood flow. Atherosclerosis begins with damage to the endothelium and is caused by high blood pressure, smoking or high cholesterol. The resulting damage leads to plaque formation.

When endothelial cells experience inflammation, they produce a molecule called “E-selectin,” which brings white blood cells (monocytes) to the area and causes plaque accumulation in the arteries.

“Our E-selectin-targeting polymer reduces existing plaque and prevents further plaque progression and inflammation, preventing arterial thrombosis, ischemia, myocardial infarction, and stroke,” says Prof. Ayelet David of the BGU Department of Clinical Biochemistry and Pharmacology.

This innovative nano-polymer has several advantages. First, it targets only damaged tissue and does not harm healthy tissue. At present, there are several available treatment options for atherosclerosis, but no other therapy reverses arterial damage and improves the heart muscle. Lastly, the polymer has no side effects, unlike statins, which are currently the leading medication used for treating atherosclerosis.

Patented and in preclinical stage, the new polymer has been tested on mice with positive results. In a study that has been submitted for publication, the researchers treated atherosclerotic mice with four injections of the new biomedical polymer and tested the change in their arteries after four weeks. “We were stunned by the results,” says Prof. David. “The myocardial function of the treated mice was greatly improved, there was less inflammation and a significant decrease in the thickness of the arteries.”

Prof. David and collaborator Prof. Jonathan Leor, director of the Cardiovascular Research Institute of the Sheba Medical Center and professor of cardiology at Tel Aviv University, suggest that this polymer-based therapy can also be helpful to people with diabetes, hypertension and other age-related conditions. “As such, the new polymeric therapy may have life-changing benefits for millions of people,” the researchers say.

“This is unprecedented,” says Prof. Leor. “We achieved an adherence level similar to that of an antibody, which may explain the strong beneficial effect we observed.”

“We are now seeking a pharmaceutical company to bring our polymer therapy through the next stages of drug development and ultimately to market,” says Dr. Ora Horovitz,  senior vice president of business development at BGN Technologies (BGN), BGU’s technology transfer and commercialization company. “We believe that this therapy has the potential to help a great number of people.”

AED Drone Delivery Service in Florida. Archer First Responders

AED Drone Delivery Service

Florida medical device CEO shares plans for AED drone delivery service

Archer First Response Systems, an automated AED drone delivery defibrillator system for cardiac arrest victims and other life-threatening emergencies, hosted its soft launch event and live demonstration at 12 p.m. on Thursday, May 4, 2017 at TrailMark, a master planned community in St. Augustine Fla.

“I am excited to officially launch our company and begin the path to installing Archer systems and providing blanket defibrillator coverage in communities across the country,” said Gordon Folkes, CEO for Archer.

“We are poised to solve a very critical problem of getting defibrillators to victims of cardiac arrest when every second counts. We are exceptionally proud of this lifesaving technology and how it can improve survival rates.”

Archer hosted the presentation and live demonstration as part of Jacksonville-based Evergreen Lifestyle Management’s annual companywide meeting, which brings together leadership from its portfolio of more than 75 communities.

“Every year we invite a company that will potentially solve a problem or provide a benefit to our communities to present at our annual meeting,” said Evergreen CEO, Kraig Carmickle.

“We are especially intrigued by the Archer system and the profound impact it could have on our residents.”

The Goodwill Partnership

PMF Joins The Goodwill Partnership

The Pumping Marvellous Foundation becomes the 55th charity partner to join TGP [The Goodwill Partnership]

 

London 8th May 2017:  The Goodwill Partnership teams up with The Pumping Marvellous Foundation, the UK’s patient led Heart Failure charity.

 

The Pumping Marvellous Foundation was founded in 2013 by a Heart Failure patient focused on the improvement of patient outcomes.  They work hand in hand with commissioners and clinicians to deliver better pathways and they are the patient voice of progression.

 

All of the potential 1,000,000 heart failure sufferers, their families and carers in the UK qualify for assistance.  Heart Failure is a progressive condition and currently has no cure.  Approximately 75% of Heart Failure diagnoses are caused by persistent unchecked hypertension or heart attacks.

 

The Pumping Marvellous Foundation offers support to sufferers of Heart Failure, including their carers and families.  Helping patients and families to self-manage their condition through coaching, giving patients a voice where representation is needed, working with clinicians and raising awareness of Heart Failure are just some of the ways in which the charity help people suffering from Heart Failure.

 

Nick Hartshorne-Evans, Founder and CEO of The Pumping Marvellous Foundations says: “We are delighted to have joined forces with The Goodwill Partnership who offer a convenient Will-writing service for both our beneficiaries and supporters.  This service will allow The Pumping Marvellous Foundation to continue the valuable work we do to help Heart Failure Patients live their lives as well as they can.”

 

Mark Jackson, Co-Founder of The Goodwill Partnership says: “As the UK’s leading patient led Heart failure charity we are delighted to be able to offer our best practice, solicitor provided Wills to The Pumping Marvellous Foundation’s supporters and volunteers who may wish to leave a legacy to the Foundation and help secure future funds.

The Goodwill Partnership

Next Generation of INR Self-Monitoring

Next Generation of INR Self-Monitoring

New survey suggests that 9 out of 10 patients on warfarin would find INR self-monitoring an easy and quick way to monitor their health

86% of patients agreed that they would consider patient INR self-monitoring to give them a life free from frequent clinic visits

Roche Diagnostics UK and Ireland launches the next generation of INR self-monitoring meter for patients on warfarin anticoagulant therapy. The new CoaguChek INRange meter allows patients to send their results to their clinic via an App on their phone using wireless connectivity.

This innovation helps to empower patients to take control of their therapy and reduce the number of clinic visits that they have to make, saving both time and money.

 

Today’s launch of the new CoaguChek INRange meter coincides with the publication of a new patient survey carried out by the Atrial Fibrillation Association. Results showed that of those patients currently on warfarin surveyed, 86% of patients agreed that they would consider patient self-monitoring to give them a life free from frequent clinic visits as they could quickly and easily send results to their healthcare professional. With the CoaguChek INRange meter, important reminders can be set up for events such as when to test or when to take medication. Comments can be added to specific results and these can be displayed in graphs, allowing patients to see how many of their results fall within their target therapeutic range.

 

Trudie Lobban MBE, Founder and CEO of the Atrial Fibrillation Association, said, “The AF Assoc. welcomes the launch of the INRange meter that can be a future-proof solution to the needs of patients on warfarin. The results of the survey showed that nearly 80% of patients would want to self-monitor giving them independence when travelling for work or pleasure”.

 

Pierre Hazlewood, Director of Point of Care, commented, “Our new meter further supports patient self-monitoring by encouraging healthcare professionals and patient dialogue via digital connectivity and App options. It also meets the needs of patients with new features and improved functionality including adding comments to a result, setting reminders and plotting results in graphs.”